Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 18.104.22.168) - Drugs in Development, 2021
Summary Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 22.214.171.124) - Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of the aromatic side-chain of phenylalanine to generate tyrosine. The enzyme works with a molecule called tetrahydrobiopterin (BH4) to carry out this chemical reaction. Tyrosine is used to make several types of hormones, certain chemicals that transmit signals in the brain (neurotransmitters), and a pigment called melanin, which gives hair and skin their color.
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 126.96.36.199) pipeline Target constitutes close to 10 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 6 and 1 respectively. Report covers products from therapy areas Metabolic Disorders which include indications Phenylketonuria (PKU) and Phenylalanine Hydroxylase Deficiencies.
The latest report Phenylalanine 4 Hydroxylase - Drugs in Development, 2021, outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 188.8.131.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 184.108.40.206) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 220.127.116.11) - The report reviews Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 18.104.22.168) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 22.214.171.124) targeted therapeutics and enlists all their major and minor projects - The report assesses Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 126.96.36.199) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 188.8.131.52) targeted therapeutics
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 184.108.40.206)Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 220.127.116.11) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
The Asia Pacific microplate readers market is expected to reach US$ 152.15 million by 2027 from US$ 110.87 million in 2019; it is estimated to grow at a CAGR of 4.1% from 2020 to 2027. The growth of the market is attributed to the factors such as technological advancements in microplate readers and consistent research in drug discovery activities....
Secondary Hyperparathyroidism (Hormonal Disorders) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Drugs in Development, 2021, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline...
125 pages •
By Global Industry Analysts
• Apr 2021
- Global Laboratory Automated Incubators Market to Reach $629.6 Million by 2027
- Amid the COVID-19 crisis, the global market for Laboratory Automated Incubators estimated at US$485.4 Million in the year 2020, is projected to reach a revised size of US$629.6 Million by 2027, growing at a CAGR of 3.8% over...
366 pages •
By Global Industry Analysts
• Apr 2021
- The global Label-Free Detection market is projected to reach US$1.3 billion by 2025, driven by growing drug R&D, rising competitive pressure to reduce cost of drug development and the resulting need for cost-effective and efficient screening technologies. Traditional label-based assays are beset with drawbacks...
Scaffold Technology Market by Product Type (Natural Scaffold and Synthetic Scaffold), by Type (Macro-porous Scaffolds, Micro-porous Scaffolds, Nano-porous Scaffolds, Solid Scaffolds), Application (Cancer Cell Research, Stem Cell Research, Drug Discovery, Regenerative Medicine, and Others), and End User (Biotechnology & Pharmaceutical...
Phenylketonuria (PKU) (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Phenylketonuria - Drugs in Development, 2021, provides an overview of the Phenylketonuria (Metabolic Disorders) pipeline landscape. Phenylketonuria...
The ePRO, epatient diaries, and eCOA market was valued at US$ 1,342.92 million in 2020 and it is projected to reach US$ 4,130.35 million by 2028; it is expected to grow at a CAGR of 15.08% during 2020-2028. Increasing demand for electronic health records (EHRs) and rising use of smartphones are fueling the market growth. However, concerns...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
The global calcium stearate market exhibited moderate growth during 2015-2020. Calcium stearate (C36H70O4.Ca) is a carboxylate of calcium that is produced by the reaction of stearic acid and calcium oxide. Also known as calcium octadecanoic acid, it has a high melting point of around 356°F and is accessible in both...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the market’s maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.